Liver Diseases in PLWH

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-26

Study Completion Date

2020-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In Highly Active Antiretroviral Therapy era, fatty liver has become an important cause of liver function damage in people living with HIV (PLWH). There are a large number of PLWH in China who are infected with hepatitis B virus and hepatitis C virus. HIV, hepatitis B virus, hepatitis C virus, drugs, alcohol, etc. affect each other, which makes the cause, diagnosis, and treatment of liver function damage in PLWH complicated in China.

The investigators plan to conduct a large-scale questionnaire survey among PLWH in Zhejiang Province to assess liver function, detect liver Injuries early, and analyze HIV, hepatitis B virus, hepatitis C virus, anti-HIV drugs, alcohol and other factors associate with liver injuries in PLWH, to provide basis for the treatment and prevention of liver disease in PLWH in eastern China.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV/AIDS Liver Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years old;
* Non-hospitalized patients diagnosed with HIV infection;
* Sign the informed consent voluntarily.

Exclusion Criteria

* Severe active infection requiring parenteral antibiotics or antifungal treatment within 30 days before the assessment;
* Other major chronic diseases that may affect health-related quality of life, such as extrahepatic malignant tumors;
* Psychotic patients, patients with severe cognitive or neurological deficits;
* Women during pregnancy and lactation;
* Those who refuse to sign informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

the first affiliated hospital of Zhejiang university school of medicine

Hangzhou, Zhejiang, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Biao Zhu, PhD.

Role: CONTACT

Phone: +86 13906535457

Email: [email protected]

Yongzheng Guo, MD.

Role: CONTACT

Phone: +86 13645814389

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yongzheng Guo, MD

Role: primary

Biao Zhu, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZJHIVER

Identifier Type: -

Identifier Source: org_study_id